{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:09:18Z","timestamp":1775855358247,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Neutrophil myeloperoxidase is involved in different inflammatory diseases, including metabolic dysfunction\u2010associated steatohepatitis (MASH). Mitiperstat is a highly potent myeloperoxidase inhibitor. This phase 2a clinical trial evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of mitiperstat in patients with non\u2010cirrhotic MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study enrolled 112 adult participants with histological MASH F1\u20133 fibrosis and increased alanine aminotransferase (ALT) levels. Participants were randomised 1:1 to once\u2010daily mitiperstat 5\u2009mg or placebo. Primary and secondary endpoints were absolute and placebo\u2010adjusted changes from baseline to week 12 in ALT and N\u2010terminal type\u2010III collagen propeptide (Pro\u2010C3) levels. Exploratory endpoints included other MASH\u2010related biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 12, there were no significant changes versus placebo for ALT (+7.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.893) and Pro\u2010C3 (\u22120.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.396), or any other MASH\u2010related biomarkers. Mitiperstat was safe and well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study does not provide proof of concept that mitiperstat 5\u2009mg exerts an anti\u2010inflammatory\/anti\u2010fibrotic effect in MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clincaltrials.gov\">ClincalTrials.gov<\/jats:ext-link>\n                      identifier: NCT05638737\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.70406","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T13:46:24Z","timestamp":1760795184000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non\u2010Cirrhotic Metabolic Dysfunction\u2010Associated Steatohepatitis"],"prefix":"10.1111","volume":"45","author":[{"given":"Javier","family":"Armisen","sequence":"first","affiliation":[{"name":"Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3919-4235","authenticated-orcid":false,"given":"Armando","family":"Flor","sequence":"additional","affiliation":[{"name":"Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Nelander","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrali S.","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5881-4998","authenticated-orcid":false,"given":"Mikael","family":"Sunn\u00e5ker","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Carter","sequence":"additional","affiliation":[{"name":"Global Patient Safety, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Trebski","sequence":"additional","affiliation":[{"name":"Global Patient Safety, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"G\u00e5rdmark","sequence":"additional","affiliation":[{"name":"Clinical Operations, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malin","family":"Aurell","sequence":"additional","affiliation":[{"name":"Clinical Operations, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Whatling","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Challis","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Vespasiani\u2010Gentilucci","sequence":"additional","affiliation":[{"name":"Research Unit of Clinical Medicine and Hepatology, Department of Medicine and Surgery Universit\u00e0 Campus bio\u2010Medico di Roma  Rome Italy"},{"name":"Unit of Hepatology Fondazione Policlinico Universitario Campus Bio\u2010Medico di Roma  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the COSMOS Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000282080"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.039"},{"key":"e_1_2_13_5_1","volume-title":"FDA Approves First Treatment for Patients With Liver Scarring due to Fatty Liver Disease","author":"US Food and Drug Administration","year":"2024"},{"key":"e_1_2_13_6_1","volume-title":"FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019","author":"US Food and Drug Administration","year":"2025"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990344"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0009-6"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02639.x"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080999"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2014.6108"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2017160588"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13855"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.04.003"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.122.001100"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052411"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12859"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.027"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42398-w"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.040"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2100"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.003"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01425-3"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100563"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:42:01Z","timestamp":1763044921000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/liv.70406"],"URL":"https:\/\/doi.org\/10.1111\/liv.70406","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"2025-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70406"}}